Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vicarious Surgical Inc. (RBOT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public surgical robotics and medical device developer. These filings offer detailed information on the Vicarious Surgical System, the company’s operating expenses, capital structure, governance and listing status.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Vicarious Surgical presents audited and interim financial statements, segment information for research and development, sales and marketing, and general and administrative activities, along with risk factors and management’s discussion of its development-stage business. Current reports on Form 8-K disclose material events such as registered direct offerings and private placements of common stock and warrants, at-the-market offering agreements, cash burn guidance, board and committee changes, and special meetings of stockholders to approve warrant exercises under New York Stock Exchange rules.
Filings also document listing and registration matters. For example, a Form 25 filed by the New York Stock Exchange relates to the removal from listing and registration of Vicarious Surgical’s publicly traded warrants, while separate 8-K items describe the NYSE’s notice to commence delisting proceedings for those warrants and the continued listing of the company’s Class A common stock under the symbol RBOT, subject to compliance with NYSE standards.
On Stock Titan, these documents are supplemented by AI-powered summaries that explain the key points of lengthy filings, such as complex financing terms, warrant structures, or at-the-market programs. Users can quickly see highlights from 10-K and 10-Q reports, understand the implications of Form 8-K events, and review proxy materials like definitive proxy statements (DEF 14A) that cover special meetings and stockholder proposals. The page also links to information about warrants, capital raises and other securities-related disclosures, helping investors and researchers analyze how Vicarious Surgical funds and governs the development of its single-port robotic surgery platform.
Adam David Sachs, President and Director of Vicarious Surgical Inc. (RBOT), sold 817 shares of Class A common stock on 08/20/2025 to satisfy tax withholding on vested restricted stock units. The sales were executed as a mandatory "sell to cover" under the company's equity plan and are not discretionary trades. The weighted average sale price was $6.0312 per share, with individual trade prices ranging from $5.90 to $6.32. After the transaction Sachs beneficially owned 49,627 shares. The Form 4 was signed by an attorney-in-fact on 08/21/2025.
Director Donald F. Tang reported open-market dispositions of Vicarious Surgical Inc. (RBOT) common stock. He sold 100 shares on 08/19/2025 at $6.68 and 2,059 shares on 08/20/2025 at $6.04, reducing his direct holdings from 45,237 shares to 43,178 shares. The form is signed by an attorney-in-fact and does not disclose any derivative transactions or additional context.
Form 144 notice for Vicarious Surgical Inc. (RBOT) reports a proposed sale of Class A common stock through UBS Financial Services. The filing shows 817 shares proposed for sale with an aggregate market value of $5,212.46 and lists the approximate sale date as 08/20/2025 on the NYSE. The securities were acquired by the reporting person on 08/19/2025 as a restricted stock lapse, with 2,378 shares noted as acquired on that date. The filing also discloses three sales by the same seller in the past three months: 817 shares on 05/20/2025 for $5,961, 463 shares on 06/03/2025 for $3,210, and 279 shares on 06/23/2025 for $2,067. The notice includes the seller’s signed representation that they are not aware of any undisclosed material adverse information about the issuer.
Vicarious Surgical Inc. (RBOT) filing is a Form 144 notice reporting proposed sales of Class A common stock by an insider. The filing lists a planned sale of 653 shares through UBS Financial Services with an aggregate market value of $4,166.14 and an approximate sale date of 08/20/2025 on the NYSE. The securities were acquired on 08/19/2025 by restricted stock lapse, showing 1,902 shares acquired in that transaction. The filer also disclosed three prior sales in the past three months totaling 1,115 shares with gross proceeds of $8,039 on 05/20/2025, 06/03/2025, and 06/23/2025. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Vicarious Surgical Inc. remains pre-revenue and reported a six-month net loss of $28.6 million and a three-month net loss of $13.2 million. Total assets declined to $40.9 million from $67.7 million, driven by lower cash and short-term investments. Cash and cash equivalents were $3.9 million and short-term investments were $20.1 million, totaling $23.96 million at June 30, 2025.
Management disclosed that these funds are insufficient to support operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern and requiring pursuit of additional equity or debt financing. The company reduced operating expenses year-over-year (R&D, G&A and S&M), improving loss from operations by ~13% for the six-month comparison. The NYSE notified the company of non-compliance with market capitalization standards but accepted the company’s cure plan for the specified review period. A CEO appointment was announced as a subsequent event.
Vicarious Surgical Inc. furnished a Current Report announcing that it issued a press release with its results for the second quarter ended June 30, 2025 and providing a business update. The 8-K attaches that press release as Exhibit 99.1 and includes an Inline XBRL cover page file as Exhibit 104. The filing states the furnished materials are not "filed" for purposes of the Exchange Act and are not incorporated by reference elsewhere unless explicitly stated. The report does not include financial tables, numerical earnings or balance sheet figures within the filing itself; readers must consult the attached press release for detailed results.
Vicarious Surgical director Ahmad Fuad acquired a stock option on June 27, 2025 giving the right to purchase 8,003 Class A common shares at an exercise price of $7.61. The option is reported as directly beneficially owned and has an expiration date of June 26, 2035.
The filing states the shares underlying the option will vest on June 27, 2026 (or one day prior to the issuer's next annual meeting), subject to continued service. The Form 4 was executed by an attorney-in-fact on August 11, 2025. The disclosure shows a routine director option grant with defined exercise price, vesting schedule, and expiration; no sales or dispositions are reported here.
Khalifa Sammy, identified as a director, a 10% owner and Chief Technology Officer of Vicarious Surgical Inc. (RBOT), reported an equity award on 06/27/2025. The filing shows acquisition of 25,025 stock options with an exercise price of $7.61. The options vest in 48 equal monthly installments beginning on the one-month anniversary of the grant, tying vesting to continued service. The options appear to carry a term that ends on 06/26/2035, and the number of derivative securities beneficially owned following the transaction is 25,025. The form is signed by an attorney-in-fact on 08/11/2025.
Donald F. Tang, a director of Vicarious Surgical Inc. (ticker: RBOT), reported receipt of a stock option on 06/27/2025. The option covers 5,335 underlying shares of Class A common stock with an exercise price of $7.61. The filing states all shares underlying the option will vest on June 27, 2026 or one day prior to the issuer's next annual meeting, whichever is earlier, provided the reporting person remains in service through the vesting date. The Form 4 shows the report was signed by an attorney-in-fact, Erin Checka, on 08/11/2025.
Clark Randolph, identified as a director of Vicarious Surgical Inc. (RBOT), reported an acquisition on Form 4 dated 06/27/2025. The filing shows an acquisition of 8,003 stock options with an exercise (conversion) price of $7.61. The options are exercisable into 8,003 shares of Class A common stock and are reported as direct ownership following the transaction.
The filing states all shares underlying the option will vest on June 27, 2026 (or one day prior to the issuer's next annual meeting), subject to continued service, and lists an associated date of 06/26/2035 in the exercisable/expiration field. The form was signed by an attorney-in-fact on 08/11/2025.